MeSH tree: C01.748.310
Cigarette smoking is widespread and deadly, yet our understanding of how cigarette smoke actually causes serious respiratory illnesses is incomplete, which has severely hampered the development of effective treatments. Today ...
Jan 17, 2025
0
29
A single 40-mg dose of the antiviral drug suraxavir marboxil significantly shortened flu symptom resolution time in male patients aged 5–65, according to research led by the China-Japan Friendship Hospital in China. Intriguingly, ...
A systematic review and meta-analysis led by Shandong University in China has evaluated the comparative efficacy and safety of antiviral medications for treating nonsevere influenza. Findings indicate that baloxavir may reduce ...
If it feels like everyone around you is fighting off a cold or recovering from the flu, it may be because respiratory illnesses are running rampant in most of the United States, and cases are only increasing.
Jan 14, 2025
0
29
The rate of infections with the flu-like human metapneumovirus (HMPV) in northern China is declining, a health official said Sunday, amid some international concern over a potential pandemic.
Jan 12, 2025
0
27
In the winter months, it seems few are safe from some kind of illness—flu, COVID-19, norovirus, colds.
Jan 11, 2025
0
67
Patients are piling up in Minnesota emergency rooms once again, but it's not just from COVID-19.
Jan 10, 2025
0
60
Researchers at the University of Gothenburg, Sweden, in collaboration with colleagues in China, have discovered an antibody-like molecule that can protect mice from various influenza viruses. The findings could pave the way ...
Jan 9, 2025
0
46
Japan in the last week of December experienced the biggest influenza outbreak since comparable data became available 25 years ago, health authorities said Thursday.
Jan 9, 2025
0
367
Reports that cases of a flu-like virus called HMPV are rising in China have sparked concern, but experts have dismissed fears that the situation is comparable to the beginnings of COVID-19 five years ago.
Jan 9, 2025
0
20
